We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

January 20, 2022

5 Digital Health Predictions for 2022

Commentary
HealthXL Team & HealthXL Community
&

HealthXLs predictions for 2022 are coming late in January so you can separate the signal from the noise. For our 2022 predictions we’ve collected inputs from the wider digital health community to give you the full picture from diverse experts. 


We predict Pharma will continue to focus on Companion DTx

The HealthXL community predicts in the next 18-24 months pharmaceutical companies are more likely to focus on companion DTx than standalone. We expect pharma will continue the trend of retrofitting digital products to their drugs as a way to differentiate them and create more valuable products. To see an increase in pharma adoption of standalone DTx, we anticipate reimbursement for these solutions will need to be comparable to existing therapies (Eg, Aetna’s policy documents indicate the payer wasn't convinced by the results of studies conducted by some DTx products). Until then, we aren’t likely to see large pharma budgets for standalone solutions. 


We predict higher quality digital endpoints will arise from the crowd

DiMe reported their crowdsource library of digital endpoints grew from 34 unique endpoints and 12 sponsors in 2019 to 225 unique endpoints and 69 sponsors by September 2021. With several hundred unique digital endpoints already on the market, there are expectations the space will only continue to grow. However, a crowded and confusing space makes it challenging to determine the best measures. We predict that amongst this crowded market, those that are being validated and utilised as primary endpoints in drug trials will gain significant attention.


We predict there will be initiatives to increase clinician digital health education

While some HCPs are eager to adopt digital health, we’ve seen challenges in this last mile delivery. For example, even though Germany has 28 approved DiGA solutions, prescriptions have not yet taken off. To drive adoption we will see new CME curriculum focused on digital health education. Programs such as Weill Cornell Medicine’s Center for Virtual Care, the  Boehringer Ingelheim DH academy, and the The Topol Programme for Digital Fellowships in Healthcare in the UK, have recently been established for practicing medical professionals. For future medical professionals, we predict digital health education will become more embedded into traditional medical school programs. Our HealthXL community believes med students could be nurtured early via university medical programs that include education around DTx and telemedicine. This could be a future solution to the adoption challenges seen today. 

We predict fewer IPOs - more M&A and hopefully more realistic valuations 

For some companies, big late stage funding rounds translated to massive valuations in 2021. In 2022 we predict there will be fewer IPOs as valuations for public and private digital health companies recalibrate to more realistic numbers. However, there may be an increase in consolidation by private equity firms of digital health companies as well as strategic M&A. Much of the M&A may come from larger corporations who can still afford high valuations and where business model pressures from changing market dynamics are acute. 


We predict digital health approvals and activations won’t be as high as people expect
We anticipate long trial times will lead to delays and drop outs in digital health reimbursement pathways. We’ve also seen countries face challenges in determining the appropriate approval criteria and regulatory bodies to vet solutions. These systematic setup delays may also decrease the number of approvals and activations seen in the next year. 

We’re looking forward to seeing all that’s to come in digital health throughout this next year! Join our HealthXL community to stay up to date on the latest trends and developments in the space. 


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: The New Reimbursement Path for Digital Health in Belgium

27th September @ 10AM GMT/5PM AWST

The right commercialization model for a digital health product is a key component of success in this rapidly growing space. Join this masterclass led by Steven Vandeput, PhD, to discuss this topic further.

Featuring
Steven Vandeput, PhD
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Featuring
Steven Vandeput, PhD
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Translating European Regulatory Guides into Practical Steps for DTx Solutions

27th September @ 10:45AM EDT

Are you trying to commercialize a digital therapeutics (DTx) solution in the European Union (EU)? Would you like to learn practical steps on how to navigate the European regulatory landscape? Keep reading, this masterclass is for you!

Featuring
Stephen Gibney
Stephen Gibney
Quality Director, BlueBridge Technologies
Featuring
Stephen Gibney
Stephen Gibney
Quality Director, BlueBridge Technologies
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

28th September @ 10AM GMT / 5PM AWST

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Join HealthXL in this peer-to-peer discussion to deep dive into this topic.

Featuring
Eugene Borukhovich
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
Anna-Maria Heidinger
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
Featuring
Eugene Borukhovich
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
Anna-Maria Heidinger
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

What are the Best Business Models for DTx in the US?

4th October @ 10:45AM EDT

What are the best models for DTx in the US in this new reality? How will the business models change in the future? Join us in a peer-to-peer conversation where we will discuss these questions and more!

Featuring
Kal Patel
Kal Patel
CEO & Co-Founder at BrightInsight
Emma Carr, PhD
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics
Featuring
Kal Patel
Kal Patel
CEO & Co-Founder at BrightInsight
Emma Carr, PhD
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
27th September @ 10AM GMT/5PM AWST

Masterclass: The New Reimbursement Path for Digital Health in Belgium

The right commercialization model for a digital health product is a key component of success in this rapidly growing space. Join this masterclass led by Steven Vandeput, PhD, to discuss this topic further.

Steven Vandeput, PhD
Featuring
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Digital Therapeutics (DTx)
27th September @ 10:45AM EDT

Masterclass: Translating European Regulatory Guides into Practical Steps for DTx Solutions

Are you trying to commercialize a digital therapeutics (DTx) solution in the European Union (EU)? Would you like to learn practical steps on how to navigate the European regulatory landscape? Keep reading, this masterclass is for you!

Stephen Gibney
Featuring
Stephen Gibney
Quality Director, BlueBridge Technologies
Telemedicine & Virtual Care Delivery
28th September @ 10:45AM EDT

What Will the Best Business Models Be for Virtual Care in Diabetes?

Join this meeting to take a deep dive into what the best business models will be in the next few years for virtual care companies in the diabetes space.

Frank Westermann
Featuring
Frank Westermann
Co-Founder & Co-CEO, 9am.health
Digital Therapeutics (DTx)
28th September @ 10AM GMT / 5PM AWST

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Join HealthXL in this peer-to-peer discussion to deep dive into this topic.

Eugene Borukhovich
Featuring
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.